MAXIMUS, Inc. (NYSE:MMS) has been assigned an average recommendation of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $79.25.
MMS has been the subject of a number of recent analyst reports. KeyCorp upgraded shares of MAXIMUS from a “sector weight” rating to an “overweight” rating and set a $80.00 price target for the company in a research report on Wednesday, June 24th. TheStreet cut shares of MAXIMUS from a “b” rating to a “c+” rating in a research report on Friday, March 13th.
In other news, Vice Chairman Richard A. Montoni sold 10,466 shares of MAXIMUS stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $72.84, for a total value of $762,343.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Vice Chairman Richard A. Montoni sold 31,398 shares of MAXIMUS stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $67.91, for a total transaction of $2,132,238.18. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC purchased a new stake in shares of MAXIMUS during the 1st quarter worth $27,000. Tower Research Capital LLC TRC boosted its position in shares of MAXIMUS by 96.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,007 shares of the health services provider’s stock worth $149,000 after purchasing an additional 984 shares in the last quarter. First Quadrant L P CA purchased a new stake in shares of MAXIMUS during the 1st quarter worth $154,000. Advisor Group Holdings Inc. purchased a new stake in shares of MAXIMUS during the 1st quarter worth $160,000. Finally, Blueshift Asset Management LLC purchased a new stake in shares of MAXIMUS in the 4th quarter worth about $221,000. 94.71% of the stock is currently owned by institutional investors.
Shares of NYSE MMS traded up $1.78 during mid-day trading on Wednesday, reaching $71.21. The company’s stock had a trading volume of 8,055 shares, compared to its average volume of 499,549. The stock has a 50-day moving average of $69.69 and a two-hundred day moving average of $68.42. The stock has a market capitalization of $4.26 billion, a P/E ratio of 21.43 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.97 and a current ratio of 1.97. MAXIMUS has a 1-year low of $46.42 and a 1-year high of $82.02.
MAXIMUS (NYSE:MMS) last released its quarterly earnings data on Thursday, May 7th. The health services provider reported $0.43 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.82 by ($0.39). MAXIMUS had a return on equity of 17.09% and a net margin of 6.71%. The firm had revenue of $818.10 million for the quarter, compared to analyst estimates of $770.28 million. During the same quarter in the previous year, the business posted $0.96 earnings per share. MAXIMUS’s revenue for the quarter was up 11.1% on a year-over-year basis. Analysts predict that MAXIMUS will post 3.02 EPS for the current fiscal year.
MAXIMUS Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.
Featured Article: What is a good dividend yield?
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.